Shirish M. Gadgeel | Thoracentesis

Dr. Gadgeel began his studies at the Grant Medical College and J.J. Group of Hospitals at the University of Bombay and graduated from the University of Mumbai Medical School in 1992. Dr. Gadgeel moved to the United States after that to complete his residency and fellowship, both at the Wayne State University. Dr. Shirish Gadgeel is a practicing lung cancer specialist and team leader of the oncology department at the Barbara Ann Karmanos Cancer Institute, with a keen interest in the treatment of mesothelioma, among a variety of other types of cancers that affect the lungs. Dr. Gadgeel is three times board certified, in hematology, medical oncology and internal medicine.

Grant Medical College and J.J. Group of Hospitals at the University of Bombay

Education

University Of Mumbai - 1992

Medical School

Wayne State University

Residency

Wayne State University

Fellowship

American Board of Internal Medicine

American Board of Internal Medicine - Hematology

American Board of Internal Medicine - Oncology

Barbara Ann Karmanos Cancer Institute

Languages: English/Spanish

(800) 527-6266

4100 John R St

Detroit, Michigan 48201

Harper University Hospital

Languages: English/Spanish

(313) 745-8040

3990 John R St

Detroit, Miami 48201

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.

Dr Alice T Shaw, MDcorrespondencePress enter key for correspondence informationemailPress enter key to Email the author, Leena Gandhi, MD, Prof Shirish Gadgeel, MD, Gregory J Riely, MD, Jeremy Cetnar, MD, Howard West, MD, D Ross Camidge, MD, Prof Mark A Socinski, MD, Alberto Chiappori, MD, Tarek Mekhail, MD, Bo H Chao, MD, Hossein Borghaei, DO, Kathryn A Gold, MD, Ali Zeaiter, MD, Walter Bordogna, PhD, Bogdana Balas, MD, Oscar Puig, PhD, Volkmar Henschel, PhD, Prof Sai-Hong Ignatius Ou, MD on behalf of the study investigators

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002J...

Gadgeel SM1, Gandhi L2, Riely GJ3, Chiappori AA4, West HL5, Azada MC6, Morcos PN7, Lee RM7, Garcia L8, Yu L7, Boisserie F7, Di Laurenzio L7, Golding S7, Sato J9, Yokoyama S9, Tanaka T9, Ou SH10.

Evaluation of Antitumor Activity Using Change in Tumor Size of the Survivin Antisense Oligonucleotide LY2181308 in Combination with Docetaxel for Second-Line Treatment...

Natale R1, Blackhall F, Kowalski D, Ramlau R, Bepler G, Grossi F, Lerchenmüller C, Pinder-Schenck M, Mezger J, Danson S, Gadgeel SM, Summers Y, Callies S, André V, Das M, Lahn M, Talbot D.

Glucocorticoid receptor status is a principal determinant of variability in the sensitivity of non-small-cell lung cancer cells to pemetrexed.

Patki M1, Gadgeel S, Huang Y, McFall T, Shields AF, Matherly LH, Bepler G, Ratnam M.

Memberships

American Society of Clinical Oncology

Southwestern Oncology Group

Bio & Insurance Information

Dr. Gadgeel began his studies at the Grant Medical College and J.J. Group of Hospitals at the University of Bombay and graduated from the University of Mumbai Medical School in 1992. Dr. Gadgeel moved to the United States after that to complete his residency and fellowship, both at the Wayne State University. Dr. Shirish Gadgeel is a practicing lung cancer specialist and team leader of the oncology department at the Barbara Ann Karmanos Cancer Institute, with a keen interest in the treatment of mesothelioma, among a variety of other types of cancers that affect the lungs. Dr. Gadgeel is three times board certified, in hematology, medical oncology and internal medicine.
Education & Training

Grant Medical College and J.J. Group of Hospitals at the University of Bombay
Education
University Of Mumbai - 1992
Medical School
Wayne State University
Residency
Wayne State University
Fellowship
Board Certifications

American Board of Internal Medicine
American Board of Internal Medicine - Hematology
American Board of Internal Medicine - Oncology
Hospital & Practice

Barbara Ann Karmanos Cancer Institute

Languages: English/Spanish

(800) 527-6266

4100 John R St

Detroit, Michigan 48201
Read More

Harper University Hospital

Languages: English/Spanish

(313) 745-8040

3990 John R St

Detroit, Miami 48201
Read More
Publications & Memberships

Dr. Shirish M. Gadgeel has contributed to 4 publications.

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.

Dr Alice T Shaw, MDcorrespondencePress enter key for correspondence informationemailPress enter key to Email the author, Leena Gandhi, MD, Prof Shirish Gadgeel, MD, Gregory J Riely, MD, Jeremy Cetnar, MD, Howard West, MD, D Ross Camidge, MD, Prof Mark A Socinski, MD, Alberto Chiappori, MD, Tarek Mekhail, MD, Bo H Chao, MD, Hossein Borghaei, DO, Kathryn A Gold, MD, Ali Zeaiter, MD, Walter Bordogna, PhD, Bogdana Balas, MD, Oscar Puig, PhD, Volkmar Henschel, PhD, Prof Sai-Hong Ignatius Ou, MD on behalf of the study investigators
See more >>

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002J...

Gadgeel SM1, Gandhi L2, Riely GJ3, Chiappori AA4, West HL5, Azada MC6, Morcos PN7, Lee RM7, Garcia L8, Yu L7, Boisserie F7, Di Laurenzio L7, Golding S7, Sato J9, Yokoyama S9, Tanaka T9, Ou SH10.
See more >>

Evaluation of Antitumor Activity Using Change in Tumor Size of the Survivin Antisense Oligonucleotide LY2181308 in Combination with Docetaxel for Second-Line Treatment...

Natale R1, Blackhall F, Kowalski D, Ramlau R, Bepler G, Grossi F, Lerchenmüller C, Pinder-Schenck M, Mezger J, Danson S, Gadgeel SM, Summers Y, Callies S, André V, Das M, Lahn M, Talbot D.
See more >>

Glucocorticoid receptor status is a principal determinant of variability in the sensitivity of non-small-cell lung cancer cells to pemetrexed.

Patki M1, Gadgeel S, Huang Y, McFall T, Shields AF, Matherly LH, Bepler G, Ratnam M.
See more >>

Memberships

American Society of Clinical Oncology

Southwestern Oncology Group

Request a call back

Request a call back

Dr. Shirish M. Gadgeel has contributed to 4 publications.

Dr. Shirish M. Gadgeel has contributed to 4 publications.